Movatterモバイル変換


[0]ホーム

URL:


SG11201400681UA - Macrocyclic compounds as protein kinase inhibitors - Google Patents

Macrocyclic compounds as protein kinase inhibitors

Info

Publication number
SG11201400681UA
SG11201400681UASG11201400681UASG11201400681UASG11201400681UASG 11201400681U ASG11201400681U ASG 11201400681UASG 11201400681U ASG11201400681U ASG 11201400681UASG 11201400681U ASG11201400681U ASG 11201400681UASG 11201400681U ASG11201400681U ASG 11201400681UA
Authority
SG
Singapore
Prior art keywords
protein kinase
kinase inhibitors
macrocyclic compounds
macrocyclic
compounds
Prior art date
Application number
SG11201400681UA
Inventor
Fernández Joaquín Pastor
Escobar Rosa María Álvarez
Fagundo Rosario Concepción Riesco
García Ana Belén García
Hergueta Antonio Rodríguez
Hernando Jose Ignacio Martín
Aparicio Carmen Blanco
Muñoz David Álvaro Cebrián
Original Assignee
Ct Nac De Investigaciones Oncológicas Cnio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Nac De Investigaciones Oncológicas CniofiledCriticalCt Nac De Investigaciones Oncológicas Cnio
Publication of SG11201400681UApublicationCriticalpatent/SG11201400681UA/en

Links

Classifications

Landscapes

SG11201400681UA2011-05-192012-05-18Macrocyclic compounds as protein kinase inhibitorsSG11201400681UA (en)

Applications Claiming Priority (3)

Application NumberPriority DateFiling DateTitle
EP113821582011-05-19
EP122750242012-03-09
PCT/GB2012/051134WO2012156756A2 (en)2011-05-192012-05-18New compounds

Publications (1)

Publication NumberPublication Date
SG11201400681UAtrue SG11201400681UA (en)2014-08-28

Family

ID=46796665

Family Applications (1)

Application NumberTitlePriority DateFiling Date
SG11201400681UASG11201400681UA (en)2011-05-192012-05-18Macrocyclic compounds as protein kinase inhibitors

Country Status (20)

CountryLink
US (2)US9284334B2 (en)
EP (1)EP2710018B8 (en)
JP (1)JP5997763B2 (en)
KR (1)KR101953210B1 (en)
CN (1)CN103748099B (en)
AU (1)AU2012257513B2 (en)
BR (1)BR112013029711B1 (en)
CA (1)CA2872979C (en)
DK (1)DK2710018T3 (en)
ES (1)ES2907071T3 (en)
HR (1)HRP20220319T1 (en)
MX (1)MX349366B (en)
NZ (1)NZ618157A (en)
PH (1)PH12013502400A1 (en)
PL (1)PL2710018T3 (en)
PT (1)PT2710018T (en)
RU (1)RU2598840C2 (en)
SG (1)SG11201400681UA (en)
WO (1)WO2012156756A2 (en)
ZA (1)ZA201309128B (en)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US9428845B1 (en)2010-12-282016-08-30Warp Drive Bio, Inc.Identifying new therapeutic agents
PH12013502400A1 (en)2011-05-192014-01-20Fundacion Del Sector Publico Estatal Centro Nac De Investigaciones Oncologicas Carlos Iii F S P CnioMacrocyclic compounds as protein kinase inhibitors
RU2622104C2 (en)*2011-09-302017-06-13Онкодизайн С.А.Macrocyclic lrrk2 kinase inhibitors
CN103788071A (en)*2012-11-012014-05-14中国人民解放军第二军医大学N-(5-(quinolyl-6-yl) pyridyl-3-yl)benzsulfamide derivatives, and preparation method and treatment use thereof
TWI574962B (en)2012-11-142017-03-21加拓科學公司Heteroaromatic compounds as pi3 kinase modulators and methods of use
EP2943485B1 (en)2013-01-142017-09-20Incyte Holdings CorporationBicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
AU2014207691B2 (en)2013-01-152018-08-30Incyte Holdings CorporationThiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors
AU2014219256B2 (en)2013-02-212017-02-16Sunshine Lake Pharma Co., Ltd.Heteroaromatic compounds as PI3 kinase modulators
EP2970297A1 (en)*2013-03-142016-01-20Bristol-Myers Squibb CompanyInhibitors of human immunodeficiency virus replication
CA2914414A1 (en)*2013-06-062014-12-11Glaxosmithkline Intellectual Property (No.2) LimitedEnhancer of zeste homolog 2 inhibitors
CN104341299B (en)*2013-07-292016-08-24漳州金富顺生物科技有限公司A kind of esterification of deodorised fat acid
EA201690458A1 (en)2013-08-232016-07-29Инсайт Корпорейшн FURO- AND THYENOPYRIDINCARBOXAMIDES USED AS PIM-KINASE INHIBITORS
CN104418853B (en)*2013-08-282016-09-07北大方正集团有限公司Substituted naphthyridines-2-ketonic compound, preparation method, purposes and pharmaceutical composition
AR097543A1 (en)*2013-09-062016-03-23Lexicon Pharmaceuticals Inc COMPOUNDS BASED ON IMIDAZO [1,2-b] PIRIDAZINE, COMPOSITIONS THAT INCLUDE THEM AND THEIR METHODS OF USE
TW201542550A (en)*2013-09-062015-11-16Lexicon Pharmaceuticals Inc Pyrazolo[1,5-a]pyrimidinyl compound, composition comprising the same, and method of using the same
JP6542236B2 (en)*2014-01-092019-07-10イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. Organic compound
US9822124B2 (en)2014-07-142017-11-21Incyte CorporationBicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9580418B2 (en)2014-07-142017-02-28Incyte CorporationBicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
CN105693744B (en)*2014-11-272018-06-19北大方正集团有限公司A kind of substituted Thienopyrimidine compound and preparation method thereof
EP3247378B8 (en)2015-01-092023-08-23Revolution Medicines, Inc.Macrocyclic compounds that participate in cooperative binding and medical uses thereof
US9540347B2 (en)2015-05-292017-01-10Incyte CorporationPyridineamine compounds useful as Pim kinase inhibitors
CN104961725B (en)*2015-06-182017-04-19浙江大学4-alpha, beta-unsaturated carboxamidoquinoline compounds and preparation and application
CN106467545B (en)*2015-08-202018-10-16北大方正集团有限公司A kind of Thienopyrimidine compound
TWI734699B (en)2015-09-092021-08-01美商英塞特公司Salts of a pim kinase inhibitor
WO2017059207A1 (en)2015-10-012017-04-06Warp Drive Bio, Inc.Methods and reagents for analyzing protein-protein interfaces
US9920032B2 (en)2015-10-022018-03-20Incyte CorporationHeterocyclic compounds useful as pim kinase inhibitors
CN109311868B (en)2015-12-222022-04-01尚医治疗有限责任公司Compounds for the treatment of cancer and inflammatory diseases
WO2017156350A1 (en)2016-03-092017-09-14K-Gen, Inc.Methods of cancer treatment
AR108301A1 (en)*2016-04-222018-08-08Astrazeneca Ab MCL-1 INHIBITORS AND SAME USE METHODS
US10947225B2 (en)2016-05-112021-03-16Emory UniversityPhosphotidylinositol 3-kinase inhibitors
ES3002745T3 (en)*2016-07-062025-03-07Univ Michigan RegentsMultifunctional inhibitors of mek/pi3k and mtor/mek/pi3k biological pathways and therapeutic methods using the same
WO2018013430A2 (en)2016-07-122018-01-18Arisan Therapeutics Inc.Heterocyclic compounds for the treatment of arenavirus infection
MX2019001125A (en)*2016-07-282019-06-12Tp Therapeutics IncMacrocycle kinase inhibitors.
CN116651422A (en)2017-03-162023-08-29沃特世科技公司Chromatographic composition
EP3642209B1 (en)2017-06-212023-11-29Shy Therapeutics LLCCompounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
JP2020531457A (en)*2017-08-152020-11-05アッヴィ・インコーポレイテッド Macrocyclic MCL-1 inhibitor and method of use
US10596161B2 (en)2017-12-082020-03-24Incyte CorporationLow dose combination therapy for treatment of myeloproliferative neoplasms
UA128407C2 (en)*2018-08-242024-07-03Байєр АкцієнгезелльшафтMethod for preparing 2-[(3r)-3-methylmorpholin-4-yl]-4-[1-methyl-1h-pyrazol-5-yl)-8-(1h-pyrazol-5-yl)-1,7-naphthyridine
EP3878854A4 (en)2018-11-092022-08-10Shandong Xuanzhu Pharma Co., Ltd. MACROCYCLIC TYROSINE KINASE INHIBITOR AND ITS APPLICATION
TW202039509A (en)*2018-12-212020-11-01美商銳新醫藥公司Compounds that participate in cooperative binding and uses thereof
CN113874015B (en)2018-12-212024-05-24细胞基因公司Thienopyridine inhibitors of RIPK2
CN109988165B (en)*2018-12-242022-10-25华东师范大学 Aromatic heterocyclic compounds as PI3K/mTOR kinase regulators and their preparation methods and applications
MX2022005359A (en)2019-11-042022-06-02Revolution Medicines IncRas inhibitors.
PE20221277A1 (en)2019-11-042022-09-05Revolution Medicines Inc RAS INHIBITORS
BR112022008535A2 (en)2019-11-042022-08-09Revolution Medicines Inc COMPOUND, PHARMACEUTICAL COMPOSITION, METHODS TO TREAT CANCER AND A RAS PROTEIN DISORDER
EP4132921A4 (en)*2020-04-092024-03-27Purdue Research Foundation PI3 KINASE INHIBITORS AND USES THEREOF
US20230183265A1 (en)*2020-05-082023-06-15Shandong Xuanzhu Pharma Co., Ltd.Crystal Form of Macrocyclic Tyrosine Kinase Inhibitor and Preparation Method therefor
CN113620976B (en)*2020-05-092023-09-26中国医学科学院药物研究所Thiazolopyrimidine compound, preparation method, application and pharmaceutical composition thereof
EP4167982A4 (en)2020-06-222024-08-07PMV Pharmaceuticals, Inc. METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION
CN116457358A (en)2020-09-152023-07-18锐新医药公司Indole derivatives as RAS inhibitors for the treatment of cancer
EP4334325A1 (en)2021-05-052024-03-13Revolution Medicines, Inc.Ras inhibitors for the treatment of cancer
CN113416181B (en)*2021-08-022022-05-03四川大学 Quinazoline derivatives and their uses
AR127308A1 (en)2021-10-082024-01-10Revolution Medicines Inc RAS INHIBITORS
CN116262758B (en)*2021-12-152025-02-28上海博悦生物科技有限公司 7-Methylthiazolo[5,4-d]pyrimidine compounds, preparation methods and uses thereof
WO2025061125A1 (en)*2023-09-222025-03-27四川汇宇制药股份有限公司Macrocyclic compound, preparation method therefor and use thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US1147478A (en)1914-11-031915-07-20Charles H BarkerWar-maneuvering game.
US5583024A (en)1985-12-021996-12-10The Regents Of The University Of CaliforniaRecombinant expression of Coleoptera luciferase
FR2601675B1 (en)1986-07-171988-09-23Rhone Poulenc Sante TAXOL DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US5750561A (en)1991-07-081998-05-12Rhone-Poulenc Rorer, S.A.Compositions containing taxane derivatives
US5698582A (en)1991-07-081997-12-16Rhone-Poulenc Rorer S.A.Compositions containing taxane derivatives
US5714512A (en)1991-07-081998-02-03Rhone-Poulenc Rorer, S.A.Compositions containing taxane derivatives
FR2698543B1 (en)1992-12-021994-12-30Rhone Poulenc Rorer Sa New taxoid-based compositions.
JPH08336393A (en)1995-04-131996-12-24Mitsubishi Chem Corp Process for producing optically active γ-substituted-β-hydroxybutyric acid ester
CZ144798A3 (en)1995-11-141998-10-14The Du Pont Merck Pharmaceutical CompanyNovel macrocyclic compounds functioning as metalloproteinase inhibitors
US6602677B1 (en)1997-09-192003-08-05Promega CorporationThermostable luciferases and methods of production
GB9800569D0 (en)1998-01-121998-03-11Glaxo Group LtdHeterocyclic compounds
ATE377597T1 (en)1999-07-092007-11-15Glaxo Group Ltd ANILINOQUINAZOLINES AS PROTEIN TYROSINE KINASE INHIBITORS
US6933299B1 (en)1999-07-092005-08-23Smithkline Beecham CorporationAnilinoquinazolines as protein tyrosine kinase inhibitors
CZ300945B6 (en)2000-06-302009-09-23Glaxo Group LimitedProcess for preparing 5-(6-quinazolinyl)-furan-2-carbaldehydes
PT1301472E (en)2000-07-192014-05-15Warner Lambert CoOxygenated esters of 4-iodo phenylamino benzhydroxamic acids
EP1353693B1 (en)2001-01-162005-03-16Glaxo Group LimitedPharmaceutical combination containing a 4-quinazolineamine and paclitaxel, carboplatin or vinorelbine for the treatment of cancer
IL149462A0 (en)2001-05-092002-11-10Warner Lambert CoMethod of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
DE10239042A1 (en)*2002-08-212004-03-04Schering AgNew fused macrocyclic pyrimidine derivatives, useful as e.g. cyclin-dependent kinase inhibitors for treating e.g. cancer, autoimmune, cardiovascular or neurodegenerative diseases or viral infections
JP2006508974A (en)2002-11-152006-03-16ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー Combination chemotherapy comprising MEK inhibitor and capecitabine (CAPECITABINE) for treating cancer
MXPA06004363A (en)2003-10-212006-06-14Warner Lambert CoPolymorphic form of n-[(r)-2, 3-dihydroxy -propoxy]-3, 4-difluoro-2 -(2-fluoro-4 -iodophenylamino) -benzamide.
EA025871B9 (en)2005-10-072017-08-31Экселиксис, Инк.Mek inhibitors and methods of using the same
WO2008049902A2 (en)2006-10-272008-05-02Janssen Pharmaceutica NvMacrocyclic quinazoline derivatives as vegfr3 inhibitors
WO2008150827A1 (en)2007-05-292008-12-11Smithkline Beecham CorporationNaphthyridine, derivatives as p13 kinase inhibitors
CN101878219B (en)2007-09-272014-04-02西班牙国家癌症研究中心Imidazolothiadiazoles for use as protein kinase inhibitors
EP2211615A4 (en)2007-10-222010-10-13Glaxosmithkline LlcPyridosulfonamide derivatives as pi3 kinase inhibitors
ES2668834T3 (en)2008-09-082018-05-22Merck Serono Sa Macrocyclic pyrimidines as protein kinase inhibitors
US8765727B2 (en)2009-01-232014-07-01Incyte CorporationMacrocyclic compounds and their use as kinase inhibitors
CA2753285A1 (en)2009-03-122010-09-16Genentech, Inc.Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies
MX2011009796A (en)*2009-03-202011-12-14Amgen IncInhibitors of pi3 kinase.
WO2010112874A1 (en)2009-04-022010-10-07Centro Nacional De Investigaciones Oncologicas (Cnio)Imidazo [2, 1-b] [ 1, 3, 4 ] thiadiazole derivatives
AU2010284254B2 (en)2009-08-172015-09-17Intellikine, LlcHeterocyclic compounds and uses thereof
PH12013502400A1 (en)2011-05-192014-01-20Fundacion Del Sector Publico Estatal Centro Nac De Investigaciones Oncologicas Carlos Iii F S P CnioMacrocyclic compounds as protein kinase inhibitors
WO2013001310A1 (en)2011-06-302013-01-03Centro Nacional De Investigaciones Oncológicas (Cnio)Macrocyclic compounds and their use as cdk8 inhibitors

Also Published As

Publication numberPublication date
BR112013029711A2 (en)2017-01-24
DK2710018T3 (en)2022-03-21
RU2598840C2 (en)2016-09-27
KR101953210B1 (en)2019-02-28
US20140256717A1 (en)2014-09-11
ES2907071T3 (en)2022-04-21
JP5997763B2 (en)2016-09-28
NZ618157A (en)2015-07-31
CA2872979C (en)2020-02-18
CN103748099A (en)2014-04-23
BR112013029711B1 (en)2020-05-12
JP2014515346A (en)2014-06-30
RU2013156361A (en)2015-06-27
HRP20220319T1 (en)2022-05-13
ZA201309128B (en)2014-08-27
EP2710018B8 (en)2022-02-23
MX349366B (en)2017-07-26
US20160296528A1 (en)2016-10-13
PT2710018T (en)2022-03-01
EP2710018B1 (en)2021-12-29
CA2872979A1 (en)2012-11-22
US9284334B2 (en)2016-03-15
WO2012156756A3 (en)2013-01-10
KR20140043092A (en)2014-04-08
MX2013013462A (en)2014-02-27
AU2012257513B2 (en)2017-05-11
CN103748099B (en)2016-08-17
AU2012257513A1 (en)2013-12-12
PH12013502400A1 (en)2014-01-20
US9808466B2 (en)2017-11-07
EP2710018A2 (en)2014-03-26
PL2710018T3 (en)2022-04-04
WO2012156756A2 (en)2012-11-22

Similar Documents

PublicationPublication DateTitle
ZA201309128B (en)Macrocyclic compounds as protein kinase inhibitors
ZA201402164B (en)Protein kinase inhibitors
EP2694517A4 (en)Protein kinase inhibitors
AP2013007252A0 (en)Heterocyclic compounds as kinase inhibitors
ZA201404156B (en)Kinase inhibitors
HUE048834T2 (en)Kinase inhibitors
ZA201402561B (en)Benzonitrile derivatives as kinase inhibitors
IL228103A0 (en)Amino-quinolines as kinase inhibitors
PT3409278T (en)Heterocyclic protein kinase inhibitors
IL229028A0 (en)Kinase inhibitors
ZA201306855B (en)Protein kinase inhibitors
EP2685992A4 (en)Amino-quinolines as kinase inhibitors
ZA201306025B (en)Phosphorus containing compounds as protein kinase inhibitors
ZA201404157B (en)Kinase inhibitors

[8]ページ先頭

©2009-2025 Movatter.jp